Dengue: Difference between revisions

(Text replacement - " pts" to " patients")
 
(13 intermediate revisions by 5 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Aedes mosquito in urban area, especially during rainy seasons in tropical/subtropic regions (Asia, Africa, Central America, Caribbean)
*Aedes mosquito in urban area, especially during rainy seasons in tropical/subtropic regions (Asia, Africa, Central America, Caribbean)
*Dengue shock syndrome and hem fever rare in travelers
*Dengue shock syndrome and hemorrhagic fever rare in travelers
**Caused by second infection of different Dengue serotype
**Caused by second infection of different Dengue serotype


Line 7: Line 7:
*Incubation 3-7 days
*Incubation 3-7 days
*Febrile phase:
*Febrile phase:
**High Fever + 'Breakbone' + GI sxs + Rash + possible exposure
**High [[fever]] + 'Breakbone' + GI symptoms + [[rash]] + possible exposure
**+/- [[Faget sign]]
**Lasts 3-7 days, majority recover
**Lasts 3-7 days, majority recover
*Critical Phase<ref>Simmons, C.P., Farrar, J.J., van Vinh Chau, N. and Wills, B. (2012) ‘Dengue’, New England Journal of Medicine, 366(15), pp. 1423–1432.</ref>:
*Critical Phase<ref>Simmons, C.P., Farrar, J.J., van Vinh Chau, N. and Wills, B. (2012) ‘Dengue’, New England Journal of Medicine, 366(15), pp. 1423–1432.</ref>:
**Minority of patients, gen. peds and elderly
**Minority of patients, generally pediatric and elderly
**Around time of defervescence
**Around time of defervescence
**Vascular leak, hypoproteinemia, hemoconcentration, pleural effusion, ascites
**Vascular leak, hypoproteinemia, hemoconcentration, [[pleural effusion]], [[ascites]]
**Narrowed pulse pressure, persistent vomiting, RUQ tenderness, lethargy and restlessness are signs of impending collapse
**Narrowed pulse pressure, persistent [[vomiting]], RUQ tenderness, lethargy and restlessness are signs of impending collapse
**Mucosal and skin bleeding
**Mucosal and skin bleeding
*"Severe Dengue," any of the following:
*"Severe Dengue," any of the following:
Line 23: Line 24:
{{Template:Fever in Traveler DDX}}
{{Template:Fever in Traveler DDX}}


==Diagnosis==
==Evaluation==
===Work-up===
===Work-up===
*Labs:  
*Labs:  
** CBC: Leukopenia, thrombocytopenia, and hemoconcentration
**CBC: [[Leukopenia]], [[thrombocytopenia]], and hemoconcentration
**CMP: LFTs elevated
**CMP: LFTs elevated
**[[DIC]] labs should be sent
**[[DIC]] labs should be sent
**Dx by 4x increase in acute/ conv titres - unlikely to be resulted in ED
**Diagnose by 4x increase in acute/ convalescent titres - unlikely to be resulted in ED
*Tourniquet Test - Tests capillary fragility
*Tourniquet Test - Tests capillary fragility
**Inflate cuff to pressure b/w SBP & DBP, and leave for 5 min
**Sensitivity of 52% and specificity of 82.4%
**(+) Test = 10-20 patechiae per square inch
**A positive tourniquet test combined with lekuopenia increases sensitivity to 94%<ref>Gregory CJ, Lorenzi OD, Colón L, García AS, Santiago LM, Rivera RC, Bermúdez LJ, Báez FO, Aponte DV, Tomashek KM, Gutierrez J, Alvarado L. Utility of the tourniquet test and the white blood cell count to differentiate dengue among acute febrile illnesses in the emergency room. PLoS Negl Trop Dis. 2011 Dec;5(12):e1400. </ref>
**Inflate cuff to pressure between SBP & DBP, and leave for 5 min
**(+) Test = 10-20 petechiae per square inch
[[File:Tourniquettest.gif|thumbnail|Example of positive tourniquet test on the right]]


===Evaluation===
===Diagnosis===
*Clinical diagnosis
*Clinical diagnosis


==Management==
==Management==
*Supportive Care
*Supportive Care
**[[APAP]] for pain/fever
**[[Acetaminophen]] for pain/fever
***DO NOT use [[ASA]] due to hemorrhagic nature
***DO NOT use [[aspirin]] due to hemorrhagic nature
*[[IVFs]]
*[[IVFs]]
*Blood [[Transfusion]] - consider in hemorrhagic shock
*Blood [[Transfusion]] - consider in hemorrhagic shock
Line 46: Line 50:
==Disposition==
==Disposition==
*Home - Well hydrated and non-toxic appearing
*Home - Well hydrated and non-toxic appearing
*Admit - High-risk patients (ie pregnant, elderly, children, chronic dz)
*Admit - High-risk patients (ie pregnant, elderly, children, chronic disease)
**ICU - patients with shock and end-organ damage
**ICU - patients with shock and end-organ damage
==Prevention==
*Vaccine available for the prevention of dengue virus and associated severe sequelae, Dengvaxia.<ref>Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1</ref>
*Only recommended for individuals 9-45 years old who have been infected once before with the virus<ref>Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1</ref>.
*If patient has confirmed or likely dengue virus infection and they live and/or work in an endemic area, have them follow up with PCP for vaccination.


==See Also==
==See Also==

Latest revision as of 18:01, 7 September 2022

Background

  • Aedes mosquito in urban area, especially during rainy seasons in tropical/subtropic regions (Asia, Africa, Central America, Caribbean)
  • Dengue shock syndrome and hemorrhagic fever rare in travelers
    • Caused by second infection of different Dengue serotype

Clinical Features

  • Incubation 3-7 days
  • Febrile phase:
    • High fever + 'Breakbone' + GI symptoms + rash + possible exposure
    • +/- Faget sign
    • Lasts 3-7 days, majority recover
  • Critical Phase[1]:
    • Minority of patients, generally pediatric and elderly
    • Around time of defervescence
    • Vascular leak, hypoproteinemia, hemoconcentration, pleural effusion, ascites
    • Narrowed pulse pressure, persistent vomiting, RUQ tenderness, lethargy and restlessness are signs of impending collapse
    • Mucosal and skin bleeding
  • "Severe Dengue," any of the following:
    • Shock from plasma leakage
    • Hemorrhage
    • Respiratory distress

Differential Diagnosis

Fever in traveler

Evaluation

Work-up

  • Labs:
    • CBC: Leukopenia, thrombocytopenia, and hemoconcentration
    • CMP: LFTs elevated
    • DIC labs should be sent
    • Diagnose by 4x increase in acute/ convalescent titres - unlikely to be resulted in ED
  • Tourniquet Test - Tests capillary fragility
    • Sensitivity of 52% and specificity of 82.4%
    • A positive tourniquet test combined with lekuopenia increases sensitivity to 94%[2]
    • Inflate cuff to pressure between SBP & DBP, and leave for 5 min
    • (+) Test = 10-20 petechiae per square inch
Example of positive tourniquet test on the right

Diagnosis

  • Clinical diagnosis

Management

Disposition

  • Home - Well hydrated and non-toxic appearing
  • Admit - High-risk patients (ie pregnant, elderly, children, chronic disease)
    • ICU - patients with shock and end-organ damage

Prevention

  • Vaccine available for the prevention of dengue virus and associated severe sequelae, Dengvaxia.[3]
  • Only recommended for individuals 9-45 years old who have been infected once before with the virus[4].
  • If patient has confirmed or likely dengue virus infection and they live and/or work in an endemic area, have them follow up with PCP for vaccination.

See Also

References

  1. Simmons, C.P., Farrar, J.J., van Vinh Chau, N. and Wills, B. (2012) ‘Dengue’, New England Journal of Medicine, 366(15), pp. 1423–1432.
  2. Gregory CJ, Lorenzi OD, Colón L, García AS, Santiago LM, Rivera RC, Bermúdez LJ, Báez FO, Aponte DV, Tomashek KM, Gutierrez J, Alvarado L. Utility of the tourniquet test and the white blood cell count to differentiate dengue among acute febrile illnesses in the emergency room. PLoS Negl Trop Dis. 2011 Dec;5(12):e1400.
  3. Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1
  4. Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021;70(No. RR-6):1–16. DOI: http://dx.doi.org/10.15585/mmwr.rr7006a1